Economical simulations for the optimal use of anti-programmed cell death-1 in advanced melanoma patients: Report of a budget impact analysis

Slimano F Roessle C Blanc C , et al. Updates on prevention and treatment of melanoma: pharmacist involvements and challenges. Ann Pharm Fr 2016; 74: 335–349.

Robert C Long GV Brady B , et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320–330.

Robert C Schachter J Long GV , et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 37: 2521–2532.

Ascierto PA Long GV Robert C , et al. Survival outcomes in patients with previously untreated BRAF wild-type advanced melanoma treated with nivolumab therapy: three-year follow-up of a randomized phase 3 trial. JAMA Oncol 2019; 5: 187–194.

Robert C Ribas A Schachter J , et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Lancet Oncol 2019; 20: 1239–1251.

European Medicines Agency. Opdivo – European public assessment report, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003985/WC500189767.pdf (2015, accessed 5 January 2020).

European Medicines Agency. Keytruda – European public assessment report, http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/003820/WC500190992.pdf (2015, accessed 5 January 2020).

Chatelut E Le Louedec F Milano G. Setting the dose of checkpoint inhibitors: the role of clinical pharmacology. Clin Pharmacokinet 2020; 59: 287–296.

Agrawal S Feng Y Roy A , et al. Nivolumab dose selection: challenges, opportunities, and lessons learned for cancer immunotherapy. J Immunother Cancer 2016; 4: 72–82.

Bajaj H Wang X Agrawal S , et al. Model-based population pharmacokinetic analysis of nivolumab in patient with solid tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6: 58–66.

Ahamadi M Freshwater T Prohn M , et al. Model-based characterization of the pharmacokinetics of pembrolizumab: a humanized anti-PD-1 monoclonal antibody in advanced solid tumors. CPT Pharmacometrics Syst Pharmacol 2017; 6: 49–57.

Freshwater T Kondic A Ahamadi M , et al. Evaluation of dosing strategy for pembrolizumab for oncology indications. J Immunother Cancer 2017; 5: 43–50.

Bristol-Myers Squibb Company. Nivolumab (Opdivo). Highlights of prescribing information, https://packageinserts.bms.com/pi/pi_opdivo.pdf (2019, accessed 5 January 2020).

Merck & Co., Inc. Pembrolizumab (Keytruda). Highlights of prescribing information, https://www.merck.com/product/usa/pi_circulars/k/keytruda/keytruda_pi.pdf (2019, accessed 5 January 2020).

Zhao X Suryawanshi S Hruska M , et al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann Oncol 2017; 28: 2002–2008.

Leven C Padelli M Carré J-L , et al. Immune checkpoint inhibitors in melanoma: a review of pharmacokinetic and exposure-response relationships. Clin Pharmacokinet 2019; 58: 1393–1405.

Bayle A Besse B Annereau M , et al. Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed dose regimen: what is the economic impact? Eur J Cancer 2019; 113: 28–31.

Long GV Tykodi SS Schneider JG , et al. Assessment of nivolumab exposure and clinical safety of 480 mg every 4 weeks flat-dosing schedule in patients with cancer. Ann Oncol 2018; 29: 2208–2213.

European Medicines Agency. Opdivo – European public assessment report, https://www.ema.europa.eu/en/documents/procedural-steps-after/opdivo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf (2019, accessed 6 January 2020).

Lala M Li M Sinha V , et al. A six-weekly (Q6W) dosing schedule for pembrolizumab based on an exposure-response (E-R) evaluation using modeling and simulation. J Clin Oncol 2018; 36: 3062.

European Medicines Agency. Keytruda – European public assessment report, https://www.ema.europa.eu/en/documents/procedural-steps-after/keytruda-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf (2019, accessed 6 January 2020).

Goldstein DA Gordon N Davidescu M , et al. A pharmacoeconomic analysis of personalized dosing vs fixed dosing of pembrolizumab in firstline PD-L1-positive non–small cell lung cancer. J Natl Cancer Inst 2017; 109–119.

de Lemos ML Kung C Waignein S. Efficacy of nivolumab four-weekly dosing schedule based on body weight. J Oncol Pharm Pract 2019; 25: 961–963.

Murphy WJ Longo DL. The surprisingly positive association between obesity and cancer immunotherapy efficacy. JAMA 2019; 321: 1247–1248.

McQuade JL Danier CR Hess KR , et al. Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy or chemotherapy: a retrospective, multicohort analysis. Lancet Oncol 2018; 19: 310–322.